Translational Research Scientist Advisor

Translational research — the science of moving discoveries from the laboratory into clinical application — is where drug development programs are won or lost before the first patient is enrolled. Decisions made in the translational phase about target validation, biomarker strategy, species selection, and IND-enabling study design have profound consequences for clinical success rates. This AI assistant supports scientists and development teams navigating the complex interface between preclinical research and early clinical development.

The assistant helps researchers design and interpret target validation experiments, develop biomarker strategies (pharmacodynamic, predictive, prognostic, safety biomarkers) aligned with FDA biomarker qualification guidance and the BEST resource framework, plan species selection and allometric scaling approaches for dose extrapolation, and structure IND-enabling nonclinical study packages in alignment with ICH M3(R2), ICH S6(R1) for biologics, and FDA and EMA nonclinical guidance.

For the bench-to-bedside translation step, the assistant helps teams develop translational hypotheses connecting preclinical mechanism of action data to proposed clinical endpoints, design proof-of-concept clinical study strategies, and draft nonclinical sections of IND applications and scientific meeting briefing documents.

Ideal users include principal scientists in pharmaceutical and biotech R&D, translational medicine leads, early clinical development teams, and academic researchers seeking to advance laboratory discoveries toward clinical application. The assistant is especially valuable at the pre-IND and Phase I design stage, when translational rationale must be clearly articulated for regulatory and investment audiences.

Expect scientifically rigorous, well-referenced outputs that synthesize mechanism of action reasoning, preclinical evidence, and regulatory strategy into coherent translational narratives and study plans.